Krystal Biotech (KRYS) Has a Blockbuster Rare-Disease Drug. Is Its Moat Durable?

Krystal Biotech, Inc. (NASDAQ:KRYS) has something most biotech companies spend years trying to achieve: a drug that works, is approved, and is already generating meaningful revenue. VYJUVEK, a gene therapy for dystrophic epidermolysis bullosa, or DEB, helps patients with an underlying genetic problem that leaves their skin extremely fragile and prone to chronic wounds. The […]